Skip to Content

Seminar. Getting it Right Early.

Where drug, device and patient experience meet the science and strategy of moving from vial to drug-device combination product.

PRESENTATIONS 12PM-4:30PM. RECEPTION 4:30-6:00PM.

Join us on this knowledge sharing seminar, designed for biopharma companies developing injectable therapies considering the transition from vials to prefilled syringes (PFS) and ultimately to integrated drug–device combination (DDC) products.  

Early choices. Lasting impact.

As injectable drug products advance through clinical trials, development teams face increasingly complex decisions that shape long-term commercial success. Choices surrounding formulation, container systems, devices, testing, and packaging often made during clinical development can significantly impact scalability, regulatory readiness, patient usability, and overall risk.

Through expert-led sessions and interactive discussion, attendees will gain practical guidance on how to future-proof their programs and confidently plan for commercialization.

Future-proof your program

Supported by industry-leading device platform providers, container and packaging specialists, and ISO-compliant testing experts, this seminar brings together the technical disciplines required to successfully bridge the clinical to commercial gap. 

  • New Brunswick, NJ - March 3, 2026
  • Cambridge, MA - March 5, 2026
  • San Francisco, CA - March 10, 2026
  • San Diego, CA - March 12, 2026

12pm-4:30pm for presentations. Reception 4:30-6:00pm.

  • Hilton East Brunswick - New Jersey
  • Royal Sonesta Hotel - Cambridge, MA
  • Embassy Suites - San Francisco Airport
  • Marriott San Diego - LaJolla

Join us and benefit from...

Our seminar partners

Learn more about our sterile capabilities that deliver quality, innovation, and reliability from development through commercialization.

Contact us today and talk to our expert customer services team about how we can support you with sterile drug development services.

Inspired by tomorrow, and with over 8000 people in 38 global GMP facilities, we support you from early-stage development through commercialization and beyond.